Global Gout Therapeutics Market 2016-2020

  • ID: 3946598
  • Report
  • Region: Global
  • 59 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Ablynx
  • Boehringer Ingelheim
  • CymaBay Therapeutics
  • Horizon Pharma
  • Lexicon Pharmaceuticals
  • Novo Nordisk
  • MORE
About Gout Therapeutics

Gout is one type of arthritis, which is caused by the high levels of uric acid in the blood. The main symptoms of gout are sudden attack of burning pain, swelling in a joint, and stiffness, usually in toe. If it is not treated, over time, it can harm tendons, joints, and other tissues. NSAIDs and urate-lowering agents are preferred treatment options for gout.

The analysts forecast the global gout therapeutics market to grow at a CAGR of 17.16% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global gout therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of gout and the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Gout Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- AstraZeneca
- Horizon Pharma
- Takeda Pharmaceuticals

Other prominent vendors
- Ablynx
- Alder Biopharmaceuticals
- Antares Pharma
- Astellas Pharma
- Boehringer Ingelheim
- Can-Fite BioPharma
- Celgene
- Celltrion
- ChemoCentryx
- CymaBay Therapeutics
- Eisai
- Eli Lilly
- Gilead Sciences
- GlaxoSmithKline
- Incyte
- Ironwood Pharmaceuticals
- JW Pharmaceutical
- KaloBios Pharmaceuticals
- Lexicon Pharmaceuticals
- LG Life Sciences
- Merck
- Morphotek
- Novartis
- Novo Nordisk
- Regeneron Pharmaceuticals
- Sandoz
- Sanofi
- Santarus
- Selecta Biosciences
- Teijin Pharma
- UCB
- Vertex Pharmaceuticals.

Market drivers
- Introduction of novel urate-lowering agents
- For a full, detailed list, view the full report

Market challenges
- Low physician and patient awareness
- For a full, detailed list, view the full report

Market trends
- Focus on regenerative medicines
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Ablynx
  • Boehringer Ingelheim
  • CymaBay Therapeutics
  • Horizon Pharma
  • Lexicon Pharmaceuticals
  • Novo Nordisk
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
PART 05: Gout: Disease overview

PART 06: Pipeline portfolio

PART 07: Market landscape
  • Market overview
  • Five forces analysis
PART 08: Key buying criteria

PART 09: Market segmentation by drug class
  • NSAIDs
  • Corticosteroids
  • Colchicine
  • Urate-lowering agents
PART 10: Market segmentation by type of disease

PART 11: Geographical segmentation
  • Gout therapeutics market in Americas
  • Gout therapeutics market in EMEA
  • Gout therapeutics market in APAC
  • Market overview
PART 12: Market drivers
  • Introduction of novel urate-lowering agents
  • Technological advancements in medical imaging
  • Popularity of off-label and OTC drugs
PART 13: Impact of drivers

PART 14: Market challenges
  • Low physician and patient awareness
  • Heavy dependency on generic drugs
  • Use of CAM for treatment of gout
PART 15: Impact of drivers and challenges

PART 16: Market trends
  • Focus on regenerative medicines
  • High growth potential of biologics
  • Preference for combination therapies
PART 17: Vendor landscape
  • Competitive scenario
  • Other prominent vendors
PART 18: Key vendor analysis
  • AstraZeneca
  • Horizon Pharma
  • Takeda Pharmaceuticals
PART 19: Appendix
  • List of abbreviations
PART 20: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Global gout therapeutics market overview
Exhibit 03: Stages of gout
Exhibit 04: Mechanism of gout
Exhibit 05: Gout: overview
Exhibit 06: Treatment algorithm for gout
Exhibit 07: Pipeline analysis of major companies for global gout therapeutics market
Exhibit 08: Share of pipeline molecules in global gout therapeutics market
Exhibit 09: Few pipeline candidates under development in global gout therapeutics market:
Exhibit 10: Market snapshot: Global gout therapeutics market
Exhibit 11: Global statistics for gout in 2015
Exhibit 12: Correlation between serum uric acid concentration and cigarette smoking status
Exhibit 13: Factors influencing the global gout therapeutics market 2015
Exhibit 14: Global gout therapeutics market snapshot: Developed and emerging markets 2015
Exhibit 15: Global gout therapeutics market 2015-2020 ($ billions)
Exhibit 16: Opportunities in gout arthritis industry today
Exhibit 17: Impact of drivers and challenges of global gout therapeutics market
Exhibit 18: Five forces analysis
Exhibit 19: Key buying criteria for gout therapeutics market
Exhibit 20: Key buying criteria for global gout therapeutics market 2015
Exhibit 21: Impact of key customer segments on global gout therapeutics market 2015
Exhibit 22: Market segmentation by drug class: Global gout therapeutics market
Exhibit 23: Common NSAIDs used for treatment of gout
Exhibit 24: Market segmentation by drug class: Present and future scenarios
Exhibit 25: Global gout therapeutics market: Segmentation by type 2015-2020
Exhibit 26: Global gout therapeutics market segmentation: Growth cycle analysis
Exhibit 27: Snapshot of global gout therapeutics market by segmentation
Exhibit 28: Snapshot of global gout therapeutics market by geography
Exhibit 29: Global gout therapeutics market revenue by geography 2015-2020 ($ millions)
Exhibit 30: Percentage share of global gout therapeutics market by geography 2015
Exhibit 31: Percentage share of global gout therapeutics market by geography 2020
Exhibit 32: Global gout therapeutics market: Country analysis based on revenue and growth rate
Exhibit 33: Gout therapeutics market in Americas 2015-2020 ($ millions)
Exhibit 34: Gout therapeutics market in EMEA 2015-2020 ($ millions)
Exhibit 35: Opportunity of RDEA3170 in APAC
Exhibit 36: Gout therapeutics market in APAC 2015-2020 ($ millions)
Exhibit 37: Phase III clinical study data and future opportunities for urate-lowering agent - Zurampic (lesinurad)
Exhibit 38: Impact of drivers
Exhibit 39: Common CAM therapies used for gout treatment
Exhibit 40: Usage of CAM therapies in US adults 2015
Exhibit 41: Impact of drivers and challenges
Exhibit 42: Impact of trends on global gout therapeutics market
Exhibit 43: Ranking of major vendors for global gout therapeutics market
Exhibit 44: Geographical presence of key vendors
Exhibit 45: Company portfolio analysis in global gout therapeutics market 2016-2020
Exhibit 46: AstraZeneca: Key highlights
Exhibit 47: AstraZeneca: Strength assessment
Exhibit 48: AstraZeneca: Strategy assessment
Exhibit 49: AstraZeneca: Opportunity assessment
Exhibit 50: Horizon Pharma: Key highlights
Exhibit 51: Horizon Pharma: Strength assessment
Exhibit 52: Horizon Pharma: Strategy assessment
Exhibit 53: Horizon Pharma: Opportunity assessment
Exhibit 54: Takeda Pharmaceuticals: Key highlights
Exhibit 55: Takeda Pharmaceuticals: Strength assessment
Exhibit 56: Takeda Pharmaceuticals: Strategy assessment
Exhibit 57: Takeda Pharmaceuticals: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Ablynx
  • Boehringer Ingelheim
  • CymaBay Therapeutics
  • Horizon Pharma
  • Lexicon Pharmaceuticals
  • Novo Nordisk
  • MORE
New Report Released: – Global Gout Therapeutics Market 2016-2020

The author of the report recognizes the following companies as the key players in the global gout therapeutics market: AstraZeneca, Horizon Pharma, and Takeda Pharmaceuticals.

Other Prominent Vendors in the market are: Ablynx, Alder Biopharmaceuticals, Antares Pharma, Astellas Pharma, Boehringer Ingelheim, Can-Fite BioPharma, Celgene, Celltrion, ChemoCentryx, CymaBay Therapeutics, Eisai, Eli Lilly, Gilead Sciences, GlaxoSmithKline, Incyte, Ironwood Pharmaceuticals, JW Pharmaceutical, KaloBios Pharmaceuticals, Lexicon Pharmaceuticals, LG Life Sciences, Merck, Morphotek, Novartis, Novo Nordisk, Regeneron Pharmaceuticals, Sandoz, Sanofi, Santarus, Selecta Biosciences, Teijin Pharma, UCB, and Vertex Pharmaceuticals.

Commenting on the report, an analyst from the research team said: “The use of regenerative medicine is an emerging treatment option for the treatment of gout. These regenerative medicines help in the healing process by replacement or regeneration of the human cells, tissues or organs, and thus help in establishing the normal function. The various regenerative techniques include cell therapy, growth factor therapy, and others.”
According to the report, introduction of novel urate-lowering agents will drive growth in this market.Urate-lowering agents are increasingly becoming the preferred choice of treatment for gout, which will be used as add-on therapy to the existing standard of care and target the gout patients who failed the previous treatment.
Further, the report states that the use of CAM for the treatment of gout is one challenge, which is expected to be increase during the forecast period. The National Arthritis Foundation reveals that more than one-third of gout arthritis patients in the US prefer CAM therapies.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- AstraZeneca
- Horizon Pharma
- Takeda Pharmaceuticals
- Ablynx
- Alder Biopharmaceuticals
- Antares Pharma
- Astellas Pharma
- Boehringer Ingelheim
- Can-Fite BioPharma
- Celgene
- Celltrion
- ChemoCentryx
- CymaBay Therapeutics
- Eisai
- Eli Lilly
- Gilead Sciences
- GlaxoSmithKline
- Incyte
- Ironwood Pharmaceuticals
- JW Pharmaceutical
- KaloBios Pharmaceuticals
- Lexicon Pharmaceuticals
- LG Life Sciences
- Merck
- Morphotek
- Novartis
- Novo Nordisk
- Regeneron Pharmaceuticals
- Sandoz
- Sanofi
- Santarus
- Selecta Biosciences
- Teijin Pharma
- UCB
- Vertex Pharmaceuticals.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll